← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

Traditional approvalTraditional conversionTumor-agnostic solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children with FDA test-confirmed MSI-high or dMMR unresectable or metastatic solid tumors after progression on prior therapy and without satisfactory alternatives.

LAMPGEN ANALYSIS

Why it matters

The action converted the biomarker-defined, tumor-agnostic indication to traditional approval.

What research teams should watch

Verify the assay, disease setting and prior treatment, and distinguish this use from the separately labeled colorectal indication.

PRIMARY RECORDS

Sources